Allergan Announces Two Clinical Trials of Brazikumab for Crohn’s Disease and Ulcerative Colitis

Allergan Announces Two Clinical Trials of Brazikumab for Crohn’s Disease and Ulcerative Colitis
Allergan recently announced two new clinical trials to the test the efficacy of its investigational therapy, Brazikumab, for treatment of two forms of inflammatory bowel disease. The two clinical trials, INTREPID and EXPEDITION, will evaluate brazikumab therapy in Crohn’s disease and ulcerative colitis, respectively. Disease-specific biomarkers will be monitored to assess the treatment outcome. EXPEDITION is currently enrolling participants; more information can be found
Subscribe or to access all post and page content.